VigilaMed Logo

FDA 21 CFR Part 820 Compliance

Navigate FDA regulations with confidence and achieve first-time submission success.

FDA 21 CFR Part 820 Expert
510(k) Submission Success
FDA Inspection Ready

The Challenge

Common pain points that prevent medical device manufacturers from achieving sustainable compliance.

Regulatory Complexity

Understanding FDA requirements and ensuring design controls meet 21 CFR Part 820 standards.

Design Control Gaps

Missing or incomplete design history files (DHF) and device master records (DMR) causing submission delays.

Inspection Readiness

Preparing for FDA inspections without knowing what they'll examine or how to respond.

The VigilaMed Solution

FDA 21 CFR Part 820 Compliance Program

We implement comprehensive FDA compliance systems covering design controls, production processes, and quality assurance. Your pathway to successful 510(k) submissions and inspection readiness.

Manufacturing-First Methodology: Our FDA expertise ensures your design controls, DHF/DMR structure, and production processes meet FDA expectations. We prepare you for every inspection scenario.

VigilaMed QARA Consultancy Logo

What You Get

Tangible deliverables that deliver immediate value and long-term compliance.

  • Design Control Procedures (21 CFR 820.30)
  • Device History File (DHF) Structure
  • Device Master Record (DMR) Template
  • FDA Inspection Preparation Guide
  • 510(k) Submission Support Documentation
  • CAPA System (FDA Compliant)

Ready to secure your compliance?

Schedule a consultation to discuss your specific compliance needs and how we can help you achieve audit-ready excellence.

VigilaMed

Regulatory Excellence for Device Manufacturers. Elite Quality & Regulatory consultancy specializing in ISO 13485, FDA compliance, and medical device manufacturing excellence.

ISO 13485:2016 Lead AuditorFDA 21 CFR Part 820 ExpertSix Sigma Yellow Belt10+ Years Manufacturing

© 2026 VigilaMed Ltd. All rights reserved. Serving Class I, II, and III device manufacturers across UK, EU, and US markets.